{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:08:55Z","timestamp":1790816935523,"version":"4.1.0"},"reference-count":224,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["129445"],"award-info":[{"award-number":["129445"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202008310151"],"award-info":[{"award-number":["202008310151"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of immune stimulants and modulators to overcome the immune dysregulation present in cancer, and leverage the host\u2019s immune capacity to eliminate tumors. Although some success has been seen in this field, toxicity and weak immune induction remain challenges. Liposomal nanosystems, previously used as targeting agents, are increasingly functioning as immunotherapeutic vehicles, with potential for delivery of contents, immune induction, and synergistic drug packaging. These systems are tailorable, multifunctional, and smart. Liposomes may deliver various immune reagents including cytokines, specific T-cell receptors, antibody fragments, and immune checkpoint inhibitors, and also present a promising platform upon which personalized medicine approaches can be built, especially with preclinical and clinical potentials of liposomes often being frustrated by inter- and intrapatient variation. In this review, we show the potential of liposomes in cancer immunotherapy, as well as the methods for synthesis and in vivo progression thereof. Both preclinical and clinical studies are included to comprehensively illuminate prospects and challenges for future research and application.<\/jats:p>","DOI":"10.3390\/pharmaceutics14010026","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:40:21Z","timestamp":1640295621000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6550-4304","authenticated-orcid":false,"given":"Seth-Frerich","family":"Fobian","sequence":"first","affiliation":[{"name":"Laboratory Experimental Oncology (LEO), Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-4465","authenticated-orcid":false,"given":"Ziyun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Laboratory Experimental Oncology (LEO), Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-7740","authenticated-orcid":false,"given":"Timo L. M.","family":"ten Hagen","sequence":"additional","affiliation":[{"name":"Laboratory Experimental Oncology (LEO), Department of Pathology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acs.accounts.9b00148","article-title":"Combining Nanomedicine and Immunotherapy","volume":"52","author":"Shi","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1016\/j.coi.2021.04.008","article-title":"Editorial overview: Cancer Immunotherapy: Are we there yet?","volume":"69","author":"Ohashi","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"eabf1244","DOI":"10.1126\/sciadv.abf1244","article-title":"In situ cancer vaccination using lipidoid nanoparticles","volume":"7","author":"Chen","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","article-title":"Immunotherapy of cancer","volume":"625","author":"Borghaei","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"a027086","DOI":"10.1101\/cshperspect.a027086","article-title":"The \u201cAchilles\u2019 Heel\u201d of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies","volume":"8","author":"Joshi","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nano.2018.12.016","article-title":"A new immune-nanoplatform for promoting adaptive antitumor immune response","volume":"17","author":"Merino","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, preparation; applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1039\/b923535n","article-title":"Liposomes as \u2018smart\u2019 pharmaceutical nanocarriers","volume":"6","author":"Sawant","year":"2010","journal-title":"Soft Matter"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amin, M., Huang, W., Seynhaeve, A.L.B., and Ten Hagen, T.L.M. (2020). Hyperthermia and Temperature-Sensitive Nanomaterials for Spatiotemporal Drug Delivery to Solid Tumors. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12111007"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1038\/s41598-021-86860-5","article-title":"Ultrasound-triggered herceptin liposomes for breast cancer therapy","volume":"11","author":"Elamir","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40495-016-0056-z","article-title":"Recent Advances in Immunoliposome-Based Cancer Therapy","volume":"2","author":"Alavizadeh","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1590","DOI":"10.1002\/wnan.1590","article-title":"Nanotechnology platforms for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog. Exp. Tumor Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2019.01.008","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (vol 175, pg 313, 2018)","volume":"176","author":"Sanmamed","year":"2019","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110639","DOI":"10.1016\/j.biopha.2020.110639","article-title":"How to overcome the side effects of tumor immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101023","DOI":"10.1016\/j.nantod.2020.101023","article-title":"Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy","volume":"36","author":"Liu","year":"2021","journal-title":"Nano Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2018-0120","article-title":"Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities","volume":"14","author":"Farjadian","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Thi, T.T.H., Suys, E.J.A., Lee, J.S., Nguyen, D.H., Park, K.D., and Truong, N.P. (2021). Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9040359"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0022-2836(64)80115-7","article-title":"Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope","volume":"8","author":"Bangham","year":"1964","journal-title":"J. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"58P","DOI":"10.1042\/bj1240058P","article-title":"Liposomes as carriers of enzymes or drugs: A new approach to the treatment of storage diseases","volume":"124","author":"Gregoriadis","year":"1971","journal-title":"Biochem. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/08982104.2019.1668010","article-title":"A comprehensive review on recent preparation techniques of liposomes","volume":"30","author":"Has","year":"2020","journal-title":"J. Liposome Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chen, X.Y., Wang, S.M., Li, N., Hu, Y., Zhang, Y., Xu, J.F., Li, X., Ren, J., Su, B., and Yuan, W.Z. (2013). Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058275"},{"key":"ref_35","first-page":"1635","article-title":"Synthesis of Ester-linked Docetaxel-glycoside Conjugate and Its Application to Drug Delivery System using Immunoliposome Targeted with Trastuzumab","volume":"11","author":"Hamada","year":"2016","journal-title":"Nat. Prod. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2007.04.013","article-title":"Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability","volume":"120","author":"Khaw","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1681\/ASN.2005050485","article-title":"Immunoliposome targeting to mesangial cells: A promising strategy for specific drug delivery to the kidney","volume":"16","author":"Tuffin","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10408390500507167","article-title":"The use of immunoliposome for nutrient target regulation (a review)","volume":"46","author":"Xianghua","year":"2006","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2009.12.020","article-title":"Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect","volume":"143","author":"Zhan","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s11671-021-03553-8","article-title":"Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy","volume":"16","author":"Rommasi","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2020.07.003","article-title":"A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer","volume":"326","author":"Jain","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.2147\/IJN.S117210","article-title":"Getting into the brain: Liposome-based strategies for effective drug delivery across the blood-brain barrier","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: Clinical developments in liposomal applications","volume":"10","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.7150\/thno.55163","article-title":"Externally triggered smart drug delivery system encapsulating idarubicin shows superior kinetics and enhances tumoral drug uptake and response","volume":"11","author":"Lu","year":"2021","journal-title":"Theranostics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1021\/la0482397","article-title":"Formation and Characterization of Phospholipid Monolayers Spontaneously Assembled at Interfaces between Aqueous Phases and Thermotropic Liquid Crystals","volume":"21","author":"Brake","year":"2005","journal-title":"Langmuir"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","article-title":"A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_47","first-page":"711","article-title":"Liposomes: An overview of manufacturing techniques","volume":"10","author":"Mozafari","year":"2005","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12604","DOI":"10.1021\/la901789h","article-title":"Curvature-Tuned Preparation of Nanoliposomes","volume":"25","author":"Ortiz","year":"2009","journal-title":"Langmuir"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10823","DOI":"10.1039\/c2sm26394g","article-title":"Formation of giant unilamellar vesicles from spin-coated lipid films by localized IR heating","volume":"8","author":"Billerit","year":"2012","journal-title":"Soft Matter"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10717540490446080","article-title":"Liposomes as Alternative Vehicles for Sun Filter Formulations","volume":"12","author":"Alonso","year":"2005","journal-title":"Drug Deliv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbamem.2017.06.003","article-title":"Diphytanoyl lipids as model systems for studying membrane-active peptides","volume":"1859","author":"Kara","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.1021\/acs.jpclett.9b03005","article-title":"Lipid Dynamics and Phase Transition within \u03b1-Synuclein Amyloid Fibrils","volume":"10","author":"Galvagnion","year":"2019","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/pharmaceutics3040848","article-title":"Exploring the Correlation Between Lipid Packaging in Lipoplexes and Their Transfection Efficacy","volume":"3","author":"Moghaddam","year":"2011","journal-title":"Pharmaceutics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Le, N.T.T., Cao, V.D., Nguyen, T.N.Q., Le, T.T.H., Tran, T.T., and Hoang Thi, T.T. (2019). Soy Lecithin-Derived Liposomal Delivery Systems: Surface Modification and Current Applications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194706"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/bi00350a001","article-title":"Destabilization of phosphatidylethanolamine liposomes at the hexagonal phase transition temperature","volume":"25","author":"Ellens","year":"1986","journal-title":"Biochemistry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0021-9258(19)42943-8","article-title":"Effects of phospholipid acyl chain fluidity, phase transitions, and cholesterol on (Na++ K+)-stimulated adenosine triphosphatase","volume":"249","author":"Kimelberg","year":"1974","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2016.10.008","article-title":"Cell membrane modulation as adjuvant in cancer therapy","volume":"52","author":"Zalba","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/09687860500453673","article-title":"Lipid rafts in T cell receptor signalling","volume":"23","author":"Kabouridis","year":"2006","journal-title":"Mol. Membr. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2014.07.058","article-title":"Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes","volume":"195","author":"Dicheva","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1104\/pp.108.119842","article-title":"Synthetic lipid (DOPG) vesicles accumulate in the cell plate region but do not fuse","volume":"147","author":"Vos","year":"2008","journal-title":"Plant Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Juszkiewicz, K., Sikorski, A.F., and Czogalla, A. (2020). Building Blocks to Design Liposomal Delivery Systems. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249559"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2020.06.027","article-title":"Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection","volume":"325","author":"Lou","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0005-2736(00)00126-7","article-title":"Biophysical and lipofection studies of DOTAP analogs","volume":"1464","author":"Regelin","year":"2000","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bielke, W., and Erbacher, C. (2010). Nucleic Acid Transfection, Springer.","DOI":"10.1007\/978-3-642-16430-9"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/IJN.S96123","article-title":"Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody","volume":"11","author":"Saeed","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-6147(94)90314-X","article-title":"Long-circulating (sterically stabilized) liposomes for targeted drug delivery","volume":"15","author":"Allen","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0005-2736(99)00186-8","article-title":"Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior","volume":"1463","author":"Hafez","year":"2000","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: Optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"22720","DOI":"10.1039\/C8NR07755J","article-title":"Dissociation of fluorescently labeled lipids from liposomes in biological environments challenges the interpretation of uptake studies","volume":"10","author":"Kristensen","year":"2018","journal-title":"Nanoscale"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Houshmand, M., Garello, F., Stefania, R., Gaidano, V., Cignetti, A., Spinelli, M., Fava, C., Nikougoftar Zarif, M., Galimberti, S., and Pungolino, E. (2021). Targeting Chronic Myeloid Leukemia Stem\/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. Cancers, 13.","DOI":"10.3390\/cancers13061311"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2017.11.035","article-title":"Hollow microneedle-mediated micro-injections of a liposomal HPV E7(43\u201363) synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses","volume":"269","author":"Heuts","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/1097-0215(20000915)87:6<829::AID-IJC12>3.0.CO;2-C","article-title":"Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats","volume":"87","author":"Nooijen","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpb.2020.05.026","article-title":"Liposomes as tunable platform to decipher the antitumor immune response triggered by TLR and NLR agonists","volume":"152","author":"Saliba","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Federizon, J., Feugmo, C.G.T., Huang, W.C., He, X., Miura, K., Razi, A., Ortega, J., Karttunen, M., and Lovell, J.F. (2021). Experimental and Computational Observations of Immunogenic Cobalt Porphyrin Lipid Bilayers: Nanodomain-Enhanced Antigen Association. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010098"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-018-2207-z","article-title":"Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma","volume":"67","author":"Gargett","year":"2018","journal-title":"Cancer Immunol. Immunother"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.7150\/thno.22056","article-title":"The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide","volume":"8","author":"Lai","year":"2018","journal-title":"Theranostics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijpharm.2017.06.003","article-title":"A novel immunoliposome mediated by CD123 antibody targeting to acute myeloid leukemia cells","volume":"529","author":"Wang","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/ie402567p","article-title":"Synthesis of Sub-100-nm Liposomes via Hydration in a Packed Bed of Colloidal Particles","volume":"53","author":"Sundar","year":"2014","journal-title":"Ind. Eng. Chem. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"14815","DOI":"10.1038\/s41598-018-33107-5","article-title":"Determination of the Main Phase Transition Temperature of Phospholipids by Nanoplasmonic Sensing","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1038\/s41598-020-60856-z","article-title":"Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles","volume":"10","author":"Rodallec","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11095-021-02986-1","article-title":"Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy","volume":"38","author":"Narayanaswamy","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/IJN.S225807","article-title":"Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma","volume":"15","author":"Hei","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/BTT.S55196","article-title":"Therapeutic vaccines and cancer: Focus on DPX-0907","volume":"8","author":"Karkada","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/intimm\/10.12.1907","article-title":"Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes","volume":"10","author":"Agrawal","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejpb.2020.04.020","article-title":"Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer","volume":"152","author":"Naciute","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2008.11.029","article-title":"Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC)","volume":"135","author":"Hirsch","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.colsurfb.2011.12.036","article-title":"Liposome and niosome preparation using a membrane contactor for scale-up","volume":"94","author":"Pham","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1021\/la070051a","article-title":"Microfluidic directed formation of liposomes of controlled size","volume":"23","author":"Jahn","year":"2007","journal-title":"Langmuir"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.chemphyslip.2017.04.003","article-title":"Spontaneous formation of single component liposomes from a solution","volume":"205","author":"Phapal","year":"2017","journal-title":"Chem. Phys. Lipids"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.addr.2020.09.003","article-title":"When liposomes met antibodies: Drug delivery and beyond","volume":"154\u2013155","author":"Di","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2017.11.035","article-title":"A simple and rapid measurement method of encapsulation efficiency of doxorubicin loaded liposomes by direct injection of the liposomal suspension to liquid chromatography","volume":"536","author":"Yamamoto","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(93)90105-9","article-title":"Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases","volume":"1151","author":"Haran","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/wnan.1450","article-title":"Stimuli-responsive liposomes for drug delivery","volume":"9","author":"Lee","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2017.11.001","article-title":"Liposome-based immunity-inducing systems for cancer immunotherapy","volume":"98","author":"Yuba","year":"2018","journal-title":"Mol. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, A., Machado, R., Gomes, A.C., and Costa, A.d. (2020). Nanotechnology Solutions for Controlled Cytokine Delivery: An Applied Perspective. Appl. Sci., 10.","DOI":"10.3390\/app10207098"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2018.02.015","article-title":"Immunoliposomes in clinical oncology: State of the art and future perspectives","volume":"275","author":"Merino","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1023\/A:1007514424253","article-title":"Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines","volume":"17","author":"Storm","year":"2000","journal-title":"Pharm. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/imt.12.26","article-title":"Particle-mediated delivery of cytokines for immunotherapy","volume":"4","author":"Christian","year":"2012","journal-title":"Immunotherapy"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0005-2736(97)00269-1","article-title":"The development of IL-2 conjugated liposomes for therapeutic purposes","volume":"1370","author":"Konigsberg","year":"1998","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13046-018-0712-8","article-title":"Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes","volume":"37","author":"Zhuo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Agger, E.M., Rosenkrands, I., Hansen, J., Brahimi, K., Vandahl, B.S., Aagaard, C., Werninghaus, K., Kirschning, C., Lang, R., and Christensen, D. (2008). Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003116"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/C6SC02403C","article-title":"Antibody fragments as nanoparticle targeting ligands: A step in the right direction","volume":"8","author":"Richards","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.colsurfb.2017.07.085","article-title":"Immunoliposomes: A review on functionalization strategies and targets for drug delivery","volume":"159","author":"Eloy","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0005-2736(01)00357-1","article-title":"In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach","volume":"1513","author":"Iden","year":"2001","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembr."},{"key":"ref_112","first-page":"23","article-title":"High efficiency reduction capability for the formation of Fab\u05f3 antibody fragments from F(ab)(2) units","volume":"2","author":"Romaschin","year":"2015","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/IJN.S190736","article-title":"Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response","volume":"14","author":"Saeed","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/antib2020193","article-title":"In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments","volume":"2","author":"Monnier","year":"2013","journal-title":"Antibodies"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv Antibody: Principles and Clinical Application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2015.01.022","article-title":"Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously","volume":"201","author":"Rabenhold","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2010.03.020","article-title":"Downregulation of EGFR by a novel multivalent nanobody-liposome platform","volume":"145","author":"Oliveira","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.12.027","article-title":"Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment","volume":"159","author":"Oliveira","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2010.11.002","article-title":"Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor","volume":"150","author":"Manjappa","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijpharm.2017.10.027","article-title":"E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells","volume":"548","author":"Gholizadeh","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/08982104.2018.1556293","article-title":"Synthesis and in vitro characterization of oxytocin receptor targeted PEGylated immunoliposomes for drug delivery to the uterus","volume":"29","author":"Hua","year":"2019","journal-title":"J. Liposome Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"FSO71","DOI":"10.4155\/fso.15.71","article-title":"Immunoliposomes doubly targeted to transferrin receptor and to \u03b1-synuclein","volume":"1","author":"Loureiro","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2015.05.284","article-title":"Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic\/prophylactic antimalarial strategy","volume":"210","author":"Moles","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-03-0041","article-title":"Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab\u2019 fragments","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12951-021-00846-z","article-title":"Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model","volume":"19","author":"Merino","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e3095","DOI":"10.1002\/btpr.3095","article-title":"Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer","volume":"37","author":"Zamani","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"104689","DOI":"10.1016\/j.oraloncology.2020.104689","article-title":"Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck","volume":"106","author":"Wang","year":"2020","journal-title":"Oral. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1704307","DOI":"10.1002\/adma.201704307","article-title":"Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials","volume":"30","author":"Bourquin","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2217\/nnm-2018-0040","article-title":"Factors relating to the biodistribution & clearance of nanoparticles & their effects on in vivo application","volume":"13","author":"Yanchun","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0304-4165(81)90259-2","article-title":"Interactions of liposomes with the reticuloendothelial system effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles","volume":"677","author":"Kao","year":"1981","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11864-021-00895-4","article-title":"Systemic Therapy for Metastatic Pancreatic Cancer","volume":"22","author":"Ettrich","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"116529","DOI":"10.1016\/j.molliq.2021.116529","article-title":"The effect of the polyethylene glycol chain length of a lipopolymer (DSPE-PEGn) on the properties of DPPC monolayers and bilayers","volume":"335","author":"Kowalska","year":"2021","journal-title":"J. Mol. Liq."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/S0100-879X1999000200006","article-title":"Liposomes: From biophysics to the design of peptide vaccines","volume":"32","author":"Frezard","year":"1999","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/JVI.05738-11","article-title":"Sensing of RNA viruses: A review of innate immune receptors involved in recognizing RNA virus invasion","volume":"86","author":"Jensen","year":"2012","journal-title":"J. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: A review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2007.11.005","article-title":"Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab\u2019 fragments and single chain Fv","volume":"126","author":"Cheng","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41551-019-0385-4","article-title":"Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models","volume":"3","author":"Kamoun","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/IJN.S197654","article-title":"Erratum in from 3D spheroids to tumor bearing mice: Efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer. Int. J. Nanomed. 2018, 13, 6677\u20136688","volume":"14","author":"Rodallec","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Wu, J. (2021). The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080771"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.1016\/j.biomaterials.2014.06.032","article-title":"Endocytosis of PEGylated nanoparticles accompanied by structural and free energy changes of the grafted polyethylene glycol","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2016.07.028","article-title":"Accumulating nanoparticles by EPR: A route of no return","volume":"238","author":"Ngoune","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Chauhan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/nn305011p","article-title":"Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors","volume":"7","author":"Sano","year":"2013","journal-title":"ACS Nano"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Haider, M., Elsherbeny, A., Pittal\u00e0, V., Fallica, A.N., Alghamdi, M.A., and Greish, K. (2021). The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. J. Pers. Med., 11.","DOI":"10.20944\/preprints202104.0679.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.rmed.2005.03.026","article-title":"Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension","volume":"99","author":"Preston","year":"2005","journal-title":"Respir. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/1061186X.2017.1405427","article-title":"Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer","volume":"26","author":"Greish","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Islam, W., Kimura, S., Islam, R., Harada, A., Ono, K., Fang, J., Niidome, T., Sawa, T., and Maeda, H. (2021). EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060487"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4049\/jimmunol.161.6.3176","article-title":"Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors","volume":"161","author":"Tutt","year":"1998","journal-title":"J. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14728222.2011.538682","article-title":"Emerging strategies for EphA2 receptor targeting for cancer therapeutics","volume":"15","author":"Tandon","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2019.08.006","article-title":"Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs","volume":"310","author":"Huang","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"111832","DOI":"10.1016\/j.msec.2020.111832","article-title":"Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy","volume":"121","author":"Jain","year":"2021","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17425247.2018.1517747","article-title":"Clinical translation of immunoliposomes for cancer therapy: Recent perspectives","volume":"15","author":"Wang","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_160","first-page":"672","article-title":"Antigen Presentation by MHC-Dressed Cells","volume":"5","author":"Nakayama","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1016\/j.vaccine.2010.03.040","article-title":"Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection","volume":"28","author":"Faurez","year":"2010","journal-title":"Vaccine"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1166\/jbn.2017.2438","article-title":"Balancing Biocompatibility, Internalization and Pharmacokinetics of Polycations\/siRNA by Structuring the Weak Negative Charged Ternary Complexes with Hyaluronic Acid","volume":"13","author":"Zhou","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"104143","DOI":"10.1016\/j.cellimm.2020.104143","article-title":"Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity","volume":"354","author":"Mai","year":"2020","journal-title":"Cell Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Naghibi, L., Yazdani, M., Momtazi-Borojeni, A.A., Razazan, A., Shariat, S., Mansourian, M., Arab, A., Barati, N., Arabsalmani, M., and Abbasi, A. (2020). Preparation of nanoliposomes containing HER2\/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243550"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2019.04.019","article-title":"MPL nano-liposomal vaccine containing P5 HER2\/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer","volume":"303","author":"Zamani","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_168","first-page":"342","article-title":"Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform","volume":"562","author":"Saliba","year":"2019","journal-title":"In. J. Pharm."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e2007165","DOI":"10.1002\/smll.202007165","article-title":"HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes","volume":"17","author":"He","year":"2021","journal-title":"Small"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.2147\/IJN.S275670","article-title":"Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice","volume":"15","author":"Zhao","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.apsb.2020.07.024","article-title":"A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41375-019-0540-7","article-title":"BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8(+) cytotoxic T lymphocytes against multiple myeloma: Clinical applications","volume":"34","author":"Bae","year":"2020","journal-title":"Leukemia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1166\/jbn.2020.2977","article-title":"Liposomes Encapsulating Neoantigens and Black Phosphorus Quantum Dots for Enhancing Photothermal Immunotherapy","volume":"16","author":"Zhang","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1016\/j.vaccine.2020.06.055","article-title":"Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma","volume":"38","author":"Yazdani","year":"2020","journal-title":"Vaccine"},{"key":"ref_175","first-page":"1065","article-title":"Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy","volume":"23","author":"Yazdani","year":"2020","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1567201813666160712164149","article-title":"Stimulation of Tumor-Specific Immunity by p5 HER-2\/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids","volume":"14","author":"Yazdani","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.imbio.2017.06.002","article-title":"Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines","volume":"222","author":"Rueda","year":"2017","journal-title":"Immunobiology"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2147\/IJN.S291421","article-title":"Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma","volume":"16","author":"Zhang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"13884","DOI":"10.1021\/acsnano.9b05037","article-title":"Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging","volume":"13","author":"Grippin","year":"2019","journal-title":"ACS Nano"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13550-018-0435-z","article-title":"In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET","volume":"8","author":"Pektor","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"102443","DOI":"10.1016\/j.nano.2021.102443","article-title":"Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy","volume":"37","author":"Yang","year":"2021","journal-title":"Nanomedicine"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"104258","DOI":"10.1016\/j.phrs.2019.104258","article-title":"Understanding and overcoming the resistance of cancer to PD-1\/PD-L1 blockade","volume":"145","author":"Shergold","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2217\/nnm-2019-0073","article-title":"Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers","volume":"14","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1479-5876-10-205","article-title":"Cancer classification using the Immunoscore: A worldwide task force","volume":"10","author":"Galon","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.7150\/thno.37574","article-title":"STING activation in cancer immunotherapy","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: Advancements and innovation in the manufacturing process","volume":"154\u2013155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients","volume":"10","author":"Berinstein","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_192","first-page":"753427","article-title":"Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory\/Suppressor Cell Proliferation and Tumor Infiltration","volume":"2013","author":"Karkada","year":"2013","journal-title":"ISRN Oncol."},{"key":"ref_193","first-page":"102","article-title":"Technology evaluation: BLP-25, Biomira Inc","volume":"3","author":"Morse","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","article-title":"Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer","volume":"23","author":"Butts","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3816\/CLC.2010.n.101","article-title":"A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer","volume":"11","author":"Butts","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.4161\/hv.29918","article-title":"Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study","volume":"10","author":"Rossmann","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.01.007","article-title":"Phase I\/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer","volume":"105","author":"Katakami","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Wu, Y.L., Park, K., Soo, R.A., Sun, Y., Tyroller, K., Wages, D., Ely, G., Yang, J.C., and Mok, T. (2011). INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-430"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(06)00494-0","article-title":"A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy","volume":"176","author":"North","year":"2006","journal-title":"J. Urol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1806680","DOI":"10.1080\/2162402X.2020.1806680","article-title":"Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: A randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)","volume":"9","author":"Schimanski","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2020.03.018","article-title":"Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)","volume":"132","author":"Singer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0005-2736(01)00377-7","article-title":"Interleukin-2-induced small unilamellar vesicle coalescence","volume":"1514","author":"Boni","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2006-12-063594","article-title":"A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma","volume":"109","author":"Neelapu","year":"2007","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-10-28","article-title":"Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]","volume":"10","author":"Hamilton","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/2051-1426-1-S1-P240","article-title":"Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer","volume":"1","author":"Nemunaitis","year":"2013","journal-title":"J. Immunother. Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2174\/15680266113136660181","article-title":"Immune senescence and vaccination in the elderly","volume":"13","author":"Lang","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2359s","DOI":"10.1158\/1078-0432.CCR-05-2537","article-title":"Immunosuppression in melanoma immunotherapy: Potential opportunities for intervention","volume":"12","author":"Lizee","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-0970-1","article-title":"Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine","volume":"60","author":"Vasievich","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e000612","DOI":"10.1136\/jitc-2020-000612","article-title":"Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine","volume":"8","author":"Pellom","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e1256527","DOI":"10.1080\/2162402X.2016.1256527","article-title":"Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles","volume":"6","author":"Sayour","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.2147\/IJN.S261671","article-title":"Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy","volume":"15","author":"Dorjsuren","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1166\/jnn.2015.9585","article-title":"Applications of Magnetic Nanoparticles in Targeted Drug Delivery System","volume":"15","author":"Mou","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejpb.2020.12.012","article-title":"ADAM 8 as a novel target for doxorubicin delivery to TNBC cells using magnetic thermosensitive liposomes","volume":"158","author":"Alawak","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1039\/D0BM01813A","article-title":"Carboxylated polyamidoamine dendron-bearing lipid-based assemblies for precise control of intracellular fate of cargo and induction of antigen-specific immune responses","volume":"9","author":"Yuba","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_216","unstructured":"(2021, December 19). DrugsUpdate. Chemo Bomb: New Cancer Treatment with Reduced Side Effects. Available online: https:\/\/www.drugsupdate.com\/news\/view\/2\/126\/chemo-bomb-new-cancer-treatment-with-reduced-side-effects."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Chong, C., Coukos, G., and Bassani-Sternberg, M. (2021). Identification of tumor antigens with immunopeptidomics. Nat. Biotechnol., 1\u201314.","DOI":"10.1038\/s41587-021-01038-8"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"e001358","DOI":"10.1136\/jitc-2020-001358","article-title":"Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy","volume":"8","author":"Nagaoka","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2020.02.004","article-title":"Hyperthermia and smart drug delivery systems for solid tumor therapy","volume":"163\u2013164","author":"Seynhaeve","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_222","first-page":"121","article-title":"Liposomes as carriers of imaging agents","volume":"1","author":"Caride","year":"1985","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/jjco\/hyp074","article-title":"Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: Cases of advanced solid tumors","volume":"39","author":"Nagamitsu","year":"2009","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"100970","DOI":"10.1016\/j.nantod.2020.100970","article-title":"Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy","volume":"35","author":"Ding","year":"2020","journal-title":"Nano Today"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/1\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:52:23Z","timestamp":1760169143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/1\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["pharmaceutics14010026"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14010026","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}